{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T21:27:33Z","timestamp":1793482053260,"version":"4.5.0"},"reference-count":111,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2018,10,10]],"date-time":"2018-10-10T00:00:00Z","timestamp":1539129600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2018,10,10]],"date-time":"2018-10-10T00:00:00Z","timestamp":1539129600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1007\/s40263-018-0580-y","type":"journal-article","created":{"date-parts":[[2018,10,10]],"date-time":"2018-10-10T04:15:52Z","timestamp":1539144952000},"page":"1131-1144","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["VMAT2 Inhibitors in Neuropsychiatric Disorders"],"prefix":"10.1007","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0409-2363","authenticated-orcid":false,"given":"Arjun","family":"Tarakad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joohi","family":"Jimenez-Shahed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,10,10]]},"reference":[{"key":"580_CR1","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1016\/j.clinthera.2012.06.010","volume":"34","author":"JJ Chen","year":"2012","unstructured":"Chen JJ, Ondo WG, Dashtipour K, Swope DM. Tetrabenazine for the treatment of hyperkinetic movement disorders: a review of the literature. Clin Ther. 2012;34:1487\u2013504.","journal-title":"Clin Ther."},{"key":"580_CR2","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1517\/21678707.2013.787358","volume":"1","author":"J Jimenez-Shahed","year":"2013","unstructured":"Jimenez-Shahed J, Jankovic J. Tetrabenazine for treatment of chorea associated with Huntington\u2019s disease and other potential indications. Expert Opin Orphan Drugs. 2013;1:423\u201336.","journal-title":"Expert Opin Orphan Drugs."},{"key":"580_CR3","first-page":"16","volume":"8","author":"G Leisman","year":"2014","unstructured":"Leisman G, Braun-Benjamin O, Melillo R. Cognitive-motor interactions of the basal ganglia in development. Front Syst Neurosci Front. 2014;8:16.","journal-title":"Front Syst Neurosci Front."},{"key":"580_CR4","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3233\/JHD-2012-120009","volume":"1","author":"L Galvan","year":"2012","unstructured":"Galvan L, Andr\u00e9 VM, Wang EA, Cepeda C, Levine MS. Functional differences between direct and indirect striatal output pathways in Huntington\u2019s disease. J Huntingt Dis. 2012;1:17\u201325.","journal-title":"J Huntingt Dis."},{"key":"580_CR5","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1212\/WNL.0b013e318263c443","volume":"79","author":"MJ Armstrong","year":"2012","unstructured":"Armstrong MJ, Miyasaki JM. Evidence-based guideline: pharmacologic treatment of chorea in Huntington disease: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology. 2012;79:597\u2013603.","journal-title":"Neurology."},{"key":"580_CR6","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1212\/WNL.0b013e31829d86b6","volume":"81","author":"R Bhidayasiri","year":"2013","unstructured":"Bhidayasiri R, Fahn S, Weiner WJ, Gronseth GS, Sullivan KL, Zesiewicz TA, et al. Evidence-based guideline: treatment of tardive syndromes: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology. 2013;81:463\u20139.","journal-title":"Neurology."},{"key":"580_CR7","first-page":"RRN1260","volume":"3","author":"J-M Burgunder","year":"2011","unstructured":"Burgunder J-M, Guttman M, Perlman S, Goodman N, van Kammen DP, Goodman L. An international survey-based algorithm for the pharmacologic treatment of chorea in Huntington\u2019s disease. PLoS Curr. 2011;3:RRN1260.","journal-title":"PLoS Curr."},{"key":"580_CR8","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s00787-011-0163-7","volume":"20","author":"V Roessner","year":"2011","unstructured":"Roessner V, Plessen KJ, Rothenberger A, Ludolph AG, Rizzo R, Skov L, et al. European clinical guidelines for Tourette syndrome and other tic disorders. Part II: pharmacological treatment. Eur Child Adolesc Psychiatry. 2011;20:173\u201396.","journal-title":"Eur Child Adolesc Psychiatry."},{"key":"580_CR9","unstructured":"Partners\/Collaborators|Neurocrine Biosciences [Internet]. https:\/\/www.neurocrine.com\/investors\/partnerscollaborators\/ . Accessed 21 Sept 2018."},{"key":"580_CR10","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1159\/000449184","volume":"23","author":"N Kaur","year":"2016","unstructured":"Kaur N, Kumar P, Jamwal S, Deshmukh R, Gauttam V. Comprehensive review tetrabenazine: spotlight on drug review. Neurosciences. 2016;23:176\u201385.","journal-title":"Neurosciences"},{"key":"580_CR11","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1124\/pr.114.010397","volume":"67","author":"CL German","year":"2015","unstructured":"German CL, Baladi MG, McFadden LM, Hanson GR, Fleckenstein AE. Regulation of the dopamine and vesicular monoamine transporters: pharmacological targets and implications for disease. Pharmacol Rev. 2015;67:1005\u201324.","journal-title":"Pharmacol Rev."},{"key":"580_CR12","unstructured":"Xenazine. Highlights of prescribing information [Internet]. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2015\/021894s010lbl.pdf . Accessed 17 Feb 2018."},{"key":"580_CR13","unstructured":"Austedo. Center for Drug Evaluation and Research [Internet]. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2017\/208082Orig1s000LBL.pdf . Accessed 17 Feb 2018."},{"key":"580_CR14","unstructured":"Ingrezza. Highlights of prescribing information [Internet]. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/209241lbl.pdf . Accessed 17 Feb 2018."},{"key":"580_CR15","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1016\/j.drudis.2014.02.006","volume":"19","author":"MD Sepers","year":"2014","unstructured":"Sepers MD, Raymond LA. Mechanisms of synaptic dysfunction and excitotoxicity in Huntington\u2019s disease. Drug Discov Today. 2014;19:990\u20136.","journal-title":"Drug Discov Today."},{"key":"580_CR16","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/B978-0-444-63425-2.00010-6","volume":"211","author":"C Cepeda","year":"2014","unstructured":"Cepeda C, Murphy KPS, Parent M, Levine MS. The role of dopamine in Huntington\u2019s disease HHS public access. Prog Brain Res. 2014;211:235\u201354.","journal-title":"Prog Brain Res."},{"key":"580_CR17","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S1474-4422(10)70245-3","volume":"10","author":"CA Ross","year":"2011","unstructured":"Ross CA, Tabrizi SJ. Huntington\u2019s disease: from molecular pathogenesis to clinical treatment. Lancet Neurol. 2011;10:83\u201398.","journal-title":"Lancet Neurol."},{"key":"580_CR18","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1111\/ene.13413","volume":"25","author":"P McColgan","year":"2018","unstructured":"McColgan P, Tabrizi SJ. Huntington\u2019s disease: a clinical review. Eur J Neurol. 2018;25:24\u201334.","journal-title":"Eur J Neurol."},{"key":"580_CR19","doi-asserted-by":"publisher","DOI":"10.7916\/D88P5Z71","author":"O Waln","year":"2013","unstructured":"Waln O, Jankovic J. An update on tardive dyskinesia: from phenomenology to treatment. Tremor Other Hyperkinet Mov. 2013. https:\/\/doi.org\/10.7916\/D88P5Z71 . pii:tre-03-161-4138-1.","journal-title":"Tremor Other Hyperkinet Mov"},{"key":"580_CR20","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1126\/science.847477","volume":"196","author":"D Burt","year":"1977","unstructured":"Burt D, Creese I, Snyder S. Antischizophrenic drugs: chronic treatment elevates dopamine receptor binding in brain. Science. 1977;196:326\u20138.","journal-title":"Science."},{"key":"580_CR21","doi-asserted-by":"crossref","first-page":"174","DOI":"10.2174\/1570159X14666160606093602","volume":"15","author":"J Yin","year":"2017","unstructured":"Yin J, Barr AM, Ramos-Miguel A, Procyshyn RM. Antipsychotic induced dopamine supersensitivity psychosis: a comprehensive review. Curr Neuropharmacol. 2017;15:174\u201383.","journal-title":"Curr Neuropharmacol."},{"key":"580_CR22","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.neuroscience.2017.07.068","volume":"361","author":"C L\u00e9vesque","year":"2017","unstructured":"L\u00e9vesque C, Hernandez G, Mahmoudi S, Calon F, Gasparini F, Gomez-Mancilla B, et al. Deficient striatal adaptation in aminergic and glutamatergic neurotransmission is associated with tardive dyskinesia in non-human primates exposed to antipsychotic drugs. Neuroscience. 2017;361:43\u201357.","journal-title":"Neuroscience."},{"key":"580_CR23","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1007\/s00221-013-3508-2","volume":"230","author":"P De Deurwaerd\u00e8re","year":"2013","unstructured":"De Deurwaerd\u00e8re P, Lagi\u00e8re M, Bosc M, Navailles S. Multiple controls exerted by 5-HT2C receptors upon basal ganglia function: from physiology to pathophysiology. Exp Brain Res. 2013;230:477\u2013511.","journal-title":"Exp Brain Res."},{"key":"580_CR24","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.expneurol.2016.09.009","volume":"286","author":"T Bordia","year":"2016","unstructured":"Bordia T, Zhang D, Perez XA, Quik M. Striatal cholinergic interneurons and D2 receptor-expressing GABAergic medium spiny neurons regulate tardive dyskinesia. Exp Neurol. 2016;286:32\u20139.","journal-title":"Exp Neurol."},{"key":"580_CR25","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1111\/pcn.12270","volume":"69","author":"PP Lerner","year":"2015","unstructured":"Lerner PP, Miodownik C, Lerner V. Tardive dyskinesia (syndrome): current concept and modern approaches to its management. Psychiatry Clin Neurosci. 2015;69:321\u201334.","journal-title":"Psychiatry Clin Neurosci."},{"key":"580_CR26","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.pnpbp.2016.02.003","volume":"70","author":"BM Kious","year":"2016","unstructured":"Kious BM, Jimenez-Shahed J, Shprecher DR. Treatment-refractory Tourette syndrome. Prog Neuropsychopharmacol Biol Psychiatry. 2016;70:227\u201336.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry."},{"key":"580_CR27","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.tins.2006.01.001","volume":"29","author":"RL Albin","year":"2006","unstructured":"Albin RL, Mink JW. Recent advances in Tourette syndrome research. Trends Neurosci. 2006;29:175\u201382.","journal-title":"Trends Neurosci."},{"key":"580_CR28","doi-asserted-by":"crossref","first-page":"12387","DOI":"10.1523\/JNEUROSCI.0150-11.2011","volume":"31","author":"RJ Felling","year":"2011","unstructured":"Felling RJ, Singer HS. Neurobiology of Tourette syndrome: current status and need for further investigation. J Neurosci. 2011;31:12387\u201395.","journal-title":"J Neurosci."},{"key":"580_CR29","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/B978-0-12-411546-0.00004-4","volume":"112","author":"PT Udvardi","year":"2013","unstructured":"Udvardi PT, Nespoli E, Rizzo F, Hengerer B, Ludolph AG. Nondopaminergic neurotransmission in the pathophysiology of Tourette syndrome. Int Rev Neurobiol. 2013;112:95\u2013130.","journal-title":"Int Rev Neurobiol."},{"key":"580_CR30","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1073\/pnas.1419533112","volume":"112","author":"M Xu","year":"2015","unstructured":"Xu M, Kobets A, Du J-C, Lennington J, Li L, Banasr M, et al. Targeted ablation of cholinergic interneurons in the dorsolateral striatum produces behavioral manifestations of Tourette syndrome. Proc Natl Acad Sci USA. 2015;112:893\u20138.","journal-title":"Proc Natl Acad Sci USA."},{"key":"580_CR31","doi-asserted-by":"crossref","first-page":"13307","DOI":"10.1073\/pnas.0502624102","volume":"102","author":"PSA Kalanithi","year":"2005","unstructured":"Kalanithi PSA, Zheng W, Kataoka Y, DiFiglia M, Grantz H, Saper CB, et al. Altered parvalbumin-positive neuron distribution in basal ganglia of individuals with Tourette syndrome. Proc Natl Acad Sci USA. 2005;102:13307\u201312.","journal-title":"Proc Natl Acad Sci USA."},{"key":"580_CR32","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1002\/cne.22206","volume":"518","author":"Y Kataoka","year":"2010","unstructured":"Kataoka Y, Kalanithi PSA, Grantz H, Schwartz ML, Saper C, Leckman JF, et al. Decreased number of parvalbumin and cholinergic interneurons in the striatum of individuals with Tourette syndrome. J Comp Neurol. 2010;518:277\u201391.","journal-title":"J Comp Neurol."},{"key":"580_CR33","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.biopsych.2014.07.018","volume":"79","author":"JB Lennington","year":"2016","unstructured":"Lennington JB, Coppola G, Kataoka-Sasaki Y, Fernandez TV, Palejev D, Li Y, et al. Transcriptome analysis of the human striatum in Tourette syndrome. Biol Psychiatry. 2016;79:372\u201382.","journal-title":"Biol Psychiatry."},{"key":"580_CR34","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1007\/s40268-017-0202-z","volume":"17","author":"H Skor","year":"2017","unstructured":"Skor H, Smith EB, Loewen G, O\u2019Brien CF, Grigoriadis DE, Bozigian H. Differences in dihydrotetrabenazine isomer concentrations following administration of tetrabenazine and valbenazine. Drugs R D. 2017;17:449\u201359.","journal-title":"Drugs R D"},{"key":"580_CR35","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1016\/j.ejmech.2011.02.046","volume":"46","author":"Z Yao","year":"2011","unstructured":"Yao Z, Wei X, Wu X, Katz JL, Kopajtic T, Greig NH, et al. Preparation and evaluation of tetrabenazine enantiomers and all eight stereoisomers of dihydrotetrabenazine as VMAT2 inhibitors. Eur J Med Chem. 2011;46:1841\u20138.","journal-title":"Eur J Med Chem"},{"key":"580_CR36","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1124\/jpet.116.239160","volume":"361","author":"DE Grigoriadis","year":"2017","unstructured":"Grigoriadis DE, Smith E, Hoare SRJ, Madan A, Bozigian H. Pharmacologic characterization of valbenazine (NBI-98854) and its metabolites. J Pharmacol Exp Ther. 2017;361:454\u201361.","journal-title":"J Pharmacol Exp Ther."},{"key":"580_CR37","doi-asserted-by":"crossref","first-page":"P2.347","DOI":"10.1212\/WNL.86.16_supplement.P2.347","volume":"86","author":"D Stamler","year":"2016","unstructured":"Stamler D, Offman E, Bradbury M, De Boer L. A randomized double-blind placebo- and positive-controlled crossover study to evaluate the effects of single doses of SD-809 (deutetrabenazine) and tetrabenazine on the corrected QT interval. Neurology. 2016;86:P2.347.","journal-title":"Neurology."},{"key":"580_CR38","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1002\/mds.25278","volume":"28","author":"R Mehanna","year":"2013","unstructured":"Mehanna R, Hunter C, Davidson A, Jimenez-Shahed J, Jankovic J. Analysis of CYP2D6 genotype and response to tetrabenazine. Mov Disord. 2013;28:210\u20135.","journal-title":"Mov Disord."},{"key":"580_CR39","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1021\/acs.biochem.7b00765","volume":"57","author":"SH DeWitt","year":"2018","unstructured":"DeWitt SH, Maryanoff BE. Deuterated drug molecules: focus on FDA-approved deutetrabenazine. Biochemistry. 2018;57:472\u20133.","journal-title":"Biochemistry."},{"key":"580_CR40","doi-asserted-by":"crossref","first-page":"44","DOI":"10.64719\/pb.4367","volume":"47","author":"R Luo","year":"2017","unstructured":"Luo R, Bozigian H, Jimenez R, Loewen G, O\u2019Brien CF. Single dose and repeat once-daily dose safety, tolerability and pharmacokinetics of valbenazine in healthy male subjects. Psychopharmacol Bull. 2017;47:44\u201352.","journal-title":"Psychopharmacol Bull"},{"key":"580_CR41","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1007\/s40264-017-0623-1","volume":"41","author":"D Thai-Cuarto","year":"2018","unstructured":"Thai-Cuarto D, O\u2019Brien CF, Jimenez R, Liang GS, Burke J. Cardiovascular profile of valbenazine: analysis of pooled data from three randomized, double-blind, placebo-controlled trials. Drug Saf. 2018;41:429\u201340.","journal-title":"Drug Saf."},{"key":"580_CR42","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1136\/bmj.2.5654.422","volume":"2","author":"MA Dalby","year":"1969","unstructured":"Dalby MA. Effect of tetrabenazine on extrapyramidal movement disorders. Br Med J. 1969;2:422\u20133.","journal-title":"Br Med J"},{"key":"580_CR43","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1136\/bmj.4.5726.55","volume":"4","author":"CA Soutar","year":"1970","unstructured":"Soutar CA. Tetrabenazine for Huntington\u2019s chorea. Br Med J. 1970;4:55.","journal-title":"Br Med J."},{"key":"580_CR44","doi-asserted-by":"crossref","first-page":"583","DOI":"10.5694\/j.1326-5377.1976.tb140870.x","volume":"1","author":"CY Huang","year":"1976","unstructured":"Huang CY, McLeod JG, Holland RT, Elliot C. Tetrabenazine in the treatment of Huntington\u2019s chorea. Med J Aust. 1976;1:583\u20134.","journal-title":"Med J Aust."},{"key":"580_CR45","first-page":"81","volume":"39","author":"JU Toglia","year":"1978","unstructured":"Toglia JU, McGlamery M, Sambandham RR. Tetrabenazine in the treatment of Huntington\u2019s chorea and other hyperkinetic movement disorders. J Clin Psychiatry. 1978;39:81\u20137.","journal-title":"J Clin Psychiatry."},{"key":"580_CR46","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1097\/00002826-200211000-00003","volume":"25","author":"WG Ondo","year":"2002","unstructured":"Ondo WG, Tintner R, Thomas M, Jankovic J. Tetrabenazine treatment for Huntington\u2019s disease-associated chorea. Clin Neuropharmacol. 2002;25:300\u20132.","journal-title":"Clin Neuropharmacol."},{"key":"580_CR47","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1212\/01.wnl.0000198586.85250.13","volume":"66","author":"Group HS","year":"2006","unstructured":"Group HS. Tetrabenazine as antichorea therapy in Huntington disease. A randomized controlled trial. Neurology. 2006;66:366\u201372.","journal-title":"Neurology."},{"key":"580_CR48","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/1471-2377-9-62","volume":"9","author":"S Frank","year":"2009","unstructured":"Frank S. Tetrabenazine as anti-chorea therapy in Huntington disease: an open-label continuation study. Huntington Study Group\/TETRA-HD Investigators. BMC Neurol Biomed Cent. 2009;9:62.","journal-title":"BMC Neurol Biomed Cent."},{"key":"580_CR49","first-page":"RRN1283","volume":"3","author":"R Dorsey","year":"2011","unstructured":"Dorsey R, Biglan K, Eberly S, Auinger P, Brocht A, Umeh CC, et al. Use of tetrabenazine in Huntington disease patients on antidepressants or with advanced disease: results from the TETRA-HD study. PLoS Curr Public Libr Sci. 2011;3:RRN1283.","journal-title":"PLoS Curr Public Libr Sci."},{"key":"580_CR50","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1212\/WNL.31.8.1051","volume":"31","author":"SW Asher","year":"1981","unstructured":"Asher SW, Aminoff MJ. Tetrabenazine and movement disorders. Neurology. 1981;31:1051\u20134.","journal-title":"Neurology."},{"key":"580_CR51","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1212\/WNL.48.2.358","volume":"48","author":"J Jankovic","year":"1997","unstructured":"Jankovic J, Beach J. Long-term effects of tetrabenazine in hyperkinetic movement disorders. Neurology. 1997;48:358\u201362.","journal-title":"Neurology."},{"key":"580_CR52","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1001\/jama.2016.8655","volume":"316","author":"S Frank","year":"2016","unstructured":"Frank S, Testa CM, Stamler D, Kayson E, Davis C, Edmondson MC, et al. Effect of deutetrabenazine on chorea among patients with Huntington disease. JAMA Am Med Assoc. 2016;316:40.","journal-title":"JAMA Am Med Assoc."},{"key":"580_CR53","unstructured":"Center for Drug Evaluation and Research Application Number: 209885Orig1s000 Other Reviews [Internet]. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2017\/209885Orig1s000OtherR.pdf . Accessed 15 Sept 2018."},{"key":"580_CR54","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1136\/bmj.4.5778.25","volume":"4","author":"RB Godwin-Austen","year":"1971","unstructured":"Godwin-Austen RB, Clark T. Persistent phenothiazine dyskinesia treated with tetrabenazine. Br Med J. 1971;4:25\u20136.","journal-title":"Br Med J."},{"key":"580_CR55","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1001\/archpsyc.1972.01750250081011","volume":"27","author":"H Kazamatsuri","year":"1972","unstructured":"Kazamatsuri H, Chien C, Cole JO. Treatment of tardive dyskinesia. Arch Gen Psychiatry Am Med Assoc. 1972;27:95.","journal-title":"Arch Gen Psychiatry Am Med Assoc."},{"key":"580_CR56","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1002\/ana.410110108","volume":"11","author":"J Jankovic","year":"1982","unstructured":"Jankovic J. Treatment of hyperkinetic movement disorders with tetrabenazine: a double-blind crossover study. Ann. Neurol. 1982;11:41\u20137.","journal-title":"Ann. Neurol."},{"key":"580_CR57","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1176\/ajp.156.8.1279","volume":"156","author":"WG Ondo","year":"1999","unstructured":"Ondo WG, Hanna PA, Jankovic J. Tetrabenazine treatment for tardive dyskinesia: assessment by randomized videotape protocol. Am Psychiatric Assoc. 1999;156:1279\u201381.","journal-title":"Am Psychiatric Assoc"},{"key":"580_CR58","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1212\/WNL.0000000000003960","volume":"88","author":"HH Fernandez","year":"2017","unstructured":"Fernandez HH, Factor SA, Hauser RA, Jimenez-Shahed J, Ondo WG, Jarskog LF, et al. Randomized controlled trial of deutetrabenazine for tardive dyskinesia: the ARM-TD study. Neurology. 2017;88:2003\u201310.","journal-title":"Neurology."},{"key":"580_CR59","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/S2215-0366(17)30236-5","volume":"4","author":"KE Anderson","year":"2017","unstructured":"Anderson KE, Stamler D, Davis MD, Factor SA, Hauser RA, Isoj\u00e4rvi J, et al. Deutetrabenazine for treatment of involuntary movements in patients with tardive dyskinesia (AIM-TD): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Psychiatry. 2017;4:595\u2013604.","journal-title":"Lancet Psychiatry."},{"key":"580_CR60","doi-asserted-by":"crossref","first-page":"S27.007","DOI":"10.1212\/WNL.0000000000002670","volume":"86","author":"S Factor","year":"2016","unstructured":"Factor S, Hauser R, Mandri D, Castro-Gayol J, Jimenez R, Siegert S, et al. A phase 2 study of valbenazine (NBI-98854) for treatment of tardive dyskinesia: KINECT 2. Neurology. 2016;86:S27.007.","journal-title":"Neurology."},{"key":"580_CR61","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1176\/appi.ajp.2017.16091037","volume":"174","author":"RA Hauser","year":"2017","unstructured":"Hauser RA, Factor SA, Marder SR, Knesevich MA, Ramirez PM, Jimenez R, et al. KINECT 3: a phase 3 randomized, double-blind, placebo-controlled trial of valbenazine for tardive dyskinesia. Am J Psychiatry. 2017;174:476\u201384.","journal-title":"Am J Psychiatry"},{"key":"580_CR62","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.4088\/JCP.17m11777","volume":"78","author":"SA Factor","year":"2017","unstructured":"Factor SA, Remington G, Comella CL, Correll CU, Burke J, Jimenez R, et al. The effects of valbenazine in participants with tardive dyskinesia. J Clin Psychiatry. 2017;78:1344\u201350.","journal-title":"J Clin Psychiatry."},{"key":"580_CR63","doi-asserted-by":"crossref","first-page":"443","DOI":"10.2165\/00044011-200828070-00006","volume":"28","author":"M Porta","year":"2008","unstructured":"Porta M, Sassi M, Cavallazzi M, Fornari M, Brambilla A, Servello D. Tourette\u2019s syndrome and role of tetrabenazine: review and personal experience. Clin Drug Investig. 2008;28:443\u201359.","journal-title":"Clin Drug Investig"},{"key":"580_CR64","first-page":"9","volume":"5","author":"CJ Kenney","year":"2007","unstructured":"Kenney CJ, Hunter CB, Mejia N, Jankovic J. Tetrabenazine in the treatment of Tourette syndrome. J Pediatr Neurol. 2007;5:9\u201313.","journal-title":"J Pediatr Neurol."},{"key":"580_CR65","doi-asserted-by":"crossref","first-page":"422","DOI":"10.5334\/tohm.287","volume":"6","author":"J Jankovic","year":"2016","unstructured":"Jankovic J, Jimenez-Shahed J, Budman C, Coffey B, Murphy T, Shprecher D, et al. Deutetrabenazine in tics associated with Tourette syndrome. Tremor Other Hyperkinet Mov. 2016;6:422.","journal-title":"Tremor Other Hyperkinet Mov."},{"key":"580_CR66","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.cct.2013.08.012","volume":"36","author":"S Jeon","year":"2013","unstructured":"Jeon S, Walkup JT, Woods DW, Peterson A, Piacentini J, Wilhelm S, et al. Detecting a clinically meaningful change in tic severity in Tourette syndrome: a comparison of three methods. Contemp Clin Trials NIH Public Access. 2013;36:414\u201320.","journal-title":"Contemp Clin Trials NIH Public Access"},{"key":"580_CR67","unstructured":"Tourette syndrome clinical trials | Neurocrine Biosciences [Internet]. http:\/\/www.neurocrine.com\/pipeline\/movements-disorder\/tourette-syndrome\/clinical-trials\/ . Accessed 17 Mar 2018."},{"key":"580_CR68","unstructured":"Neurocrine announces phase II results of VMAT2 inhibitor INGREZZA\u00ae for treatment of Tourette [Internet]. https:\/\/www.prnewswire.com\/news-releases\/neurocrine-announces-phase-ii-results-of-vmat2-inhibitor-ingrezza-for-treatment-of-tourette-syndrome-300462596.html . Accessed 29 Apr 2018."},{"key":"580_CR69","first-page":"101","volume":"28","author":"L Brusa","year":"2013","unstructured":"Brusa L, Orlacchio A, Stefani A, Galati S, Pierantozzi M, Iani C, et al. Tetrabenazine improves levodopa-induced peak-dose dyskinesias in patients with Parkinson\u2019s disease. Funct Neurol. 2013;28:101\u20135.","journal-title":"Funct Neurol."},{"key":"580_CR70","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1002\/mds.21222","volume":"22","author":"C Kenney","year":"2007","unstructured":"Kenney C, Hunter C, Jankovic J. Long-term tolerability of tetrabenazine in the treatment of hyperkinetic movement disorders. Mov Disord. 2007;22:193\u20137.","journal-title":"Mov Disord."},{"key":"580_CR71","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1212\/WNL.38.3.391","volume":"38","author":"J Jankovic","year":"1988","unstructured":"Jankovic J, Orman J. Tetrabenazine therapy of dystonia, chorea, tics, and other dyskinesias. Neurology. 1988;38:391\u20134.","journal-title":"Neurology."},{"key":"580_CR72","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1176\/appi.neuropsych.11030077","volume":"24","author":"WG Ondo","year":"2012","unstructured":"Ondo WG. Tetrabenazine treatment for stereotypies and tics associated with dementia. J Neuropsychiatry Clin Neurosci. 2012;24:208\u201314.","journal-title":"J Neuropsychiatry Clin Neurosci."},{"key":"580_CR73","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1002\/mdc3.12483","volume":"4","author":"FB Rodrigues","year":"2017","unstructured":"Rodrigues FB, Duarte GS, Costa J, Ferreira JJ, Wild EJ. Tetrabenazine versus deutetrabenazine for Huntington\u2019s disease: twins or distant cousins? Mov Disord Clin Pract. 2017;4:582\u20135.","journal-title":"Mov Disord Clin Pract."},{"key":"580_CR74","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s40734-017-0051-5","volume":"4","author":"DO Claassen","year":"2017","unstructured":"Claassen DO, Carroll B, De Boer LM, Wu E, Ayyagari R, Gandhi S, et al. Indirect tolerability comparison of deutetrabenazine and tetrabenazine for Huntington disease. J Clin Mov Disord. 2017;4:3.","journal-title":"J Clin Mov Disord."},{"key":"580_CR75","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1001\/jamaneurol.2017.1352","volume":"74","author":"S Frank","year":"2017","unstructured":"Frank S, Stamler D, Kayson E, Claassen DO, Colcher A, Davis C, et al. Safety of converting from tetrabenazine to deutetrabenazine for the treatment of chorea. JAMA Neurol Am Med Assoc. 2017;74:977.","journal-title":"JAMA Neurol Am Med Assoc."},{"key":"580_CR76","doi-asserted-by":"crossref","first-page":"S27.001","DOI":"10.1212\/WNL.86.16_supplement.S27.001","volume":"86","author":"M Bari","year":"2016","unstructured":"Bari M, Shiwach R, Jimenez R, Siegert S, O\u2019Brien C. Open-label extension of KINECT: a phase 2 Study of valbenazine (NBI-98854) for tardive dyskinesia. Neurology. 2016;86:S27.001.","journal-title":"Neurology."},{"key":"580_CR77","first-page":"S159","volume":"32","author":"H Fernandez","year":"2017","unstructured":"Fernandez H, Stamler D, Davis M, Factor S, Hauser R, Isoj\u00e4rvi J, et al. Evaluation of patient-reported outcomes in tardive dyskinesia patients with underlying psychotic and mood disorders in the ARM-TD and AIM-TD trials [abstract]. Mov Disord. 2017;32:S159\u201360.","journal-title":"Mov Disord"},{"key":"580_CR78","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1080\/14737175.2017.1386556","volume":"17","author":"T M\u00fcller","year":"2017","unstructured":"M\u00fcller T. Valbenazine for the treatment of tardive dyskinesia. Expert Rev Neurother. 2017;17:1135\u201344.","journal-title":"Expert Rev Neurother."},{"key":"580_CR79","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1002\/ana.23672","volume":"72","author":"SM Murphy","year":"2012","unstructured":"Murphy SM, Puwanant A, Griggs RC, Consortium for Clinical Investigations of Neurological Channelopathies (CINCH) and Inherited Neuropathies Consortium (INC) Consortia of the Rare Disease Clinical Research Network the C and IC of the RDCR. Unintended effects of orphan product designation for rare neurological diseases. Ann Neurol NIH Public Access. 2012;72:481\u201390.","journal-title":"Ann Neurol NIH Public Access."},{"key":"580_CR80","unstructured":"INGREZZA\u00ae (valbenazine) HCP support and resources [Internet]. https:\/\/ingrezzahcp.com\/ingrezza-support-resources . Accessed 23 Mar 2018."},{"key":"580_CR81","unstructured":"Getting started|AUSTEDO\u00ae (deutetrabenazine) tablets [Internet]. https:\/\/austedo.com\/hcp\/getting-started . Accessed 23 Mar 2018."},{"key":"580_CR82","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1097\/DBP.0000000000000065","volume":"35","author":"RH Bitsko","year":"2014","unstructured":"Bitsko RH, Holbrook JR, Visser SN, Mink JW, Zinner SH, Ghandour RM, et al. A national profile of Tourette syndrome, 2011\u20132012. J Dev Behav Pediatr. 2014;35:317\u201322.","journal-title":"J Dev Behav Pediatr."},{"key":"580_CR83","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1177\/107424840100600306","volume":"6","author":"B Drolet","year":"2001","unstructured":"Drolet B, Rousseau G, Daleau P, Cardinal R, Simard C, Turgeon J. Pimozide (Orap\u00ae) prolongs cardiac repolarization by blocking the rapid component of the delayed rectifier potassium current in native cardiac myocytes. J Cardiovasc Pharmacol Ther. 2001;6:255\u201360.","journal-title":"J Cardiovasc Pharmacol Ther."},{"key":"580_CR84","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1002\/mds.26414","volume":"30","author":"J Jankovic","year":"2015","unstructured":"Jankovic J. Therapeutic developments for tics and myoclonus. Mov Disord. 2015;30:1566\u201373.","journal-title":"Mov Disord."},{"key":"580_CR85","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1001\/archpsyc.1989.01810080052006","volume":"46","author":"E Shapiro","year":"1989","unstructured":"Shapiro E, Shapiro AK, Fulop G, Hubbard M, Mandeli J, Nordlie J, et al. Controlled study of haloperidol, pimozide and placebo for the treatment of Gilles de la Tourette\u2019s syndrome. Arch Gen Psychiatry. 1989;46:722\u201330.","journal-title":"Arch Gen Psychiatry."},{"key":"580_CR86","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1212\/01.WNL.0000055434.39968.67","volume":"60","author":"L Scahill","year":"2003","unstructured":"Scahill L, Leckman JF, Schultz RT, Katsovich L, Peterson BS. A placebo-controlled trial of risperidone in Tourette syndrome. Neurology. 2003;60:1130\u20135.","journal-title":"Neurology."},{"key":"580_CR87","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/BF00431840","volume":"56","author":"J Gerlach","year":"1978","unstructured":"Gerlach J, Rye T, Kristjansen P. Effect of baclofen on tardive dyskinesia. Psychopharmacology (Berl). 1978;56:145\u201351.","journal-title":"Psychopharmacology (Berl)."},{"key":"580_CR88","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1097\/00002826-198212000-00004","volume":"5","author":"RM Stewart","year":"1982","unstructured":"Stewart RM, Rollins J, Beckham B, Roffman M. Baclofen in tardive dyskinesia patients maintained on neuroleptics. Clin. Neuropharmacol. 1982;5:365\u201373.","journal-title":"Clin. Neuropharmacol."},{"key":"580_CR89","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1007\/BF00432517","volume":"87","author":"WM Glazer","year":"1985","unstructured":"Glazer WM, Moore DC, Bowers MB, Bunney BS, Roffman M. The treatment of tardive dyskinesia with baclofen. Psychopharmacology (Berl). 1985;87:480\u20133.","journal-title":"Psychopharmacology (Berl)."},{"key":"580_CR90","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1212\/WNL.56.5.599","volume":"56","author":"HS Singer","year":"2001","unstructured":"Singer HS, Wendlandt J, Krieger M, Giuliano J. Baclofen treatment in Tourette syndrome: a double-blind, placebo-controlled, crossover trial. Neurology. 2001;56:599\u2013604.","journal-title":"Neurology."},{"key":"580_CR91","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1176\/ajp.147.4.445","volume":"147","author":"GK Thaker","year":"1990","unstructured":"Thaker GK, Nguyen JA, Strauss ME, Jacobson R, Kaup BA, Tamminga CA. Clonazepam treatment of tardive dyskinesia: a practical GABAmimetic strategy. Am J Psychiatry. 1990;147:445\u201351.","journal-title":"Am J Psychiatry."},{"key":"580_CR92","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/0361-9230(83)90188-0","volume":"11","author":"MM Singh","year":"1983","unstructured":"Singh MM, Becker RE, Pitman RK, Nasrallah HA, Lal H. Sustained improvement in tardive dyskinesia with diazepam: indirect evidence for corticolimbic involvement. Brain Res Bull. 1983;11:179\u201385.","journal-title":"Brain Res Bull."},{"key":"580_CR93","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1136\/jnnp.2009.185348","volume":"81","author":"J Jankovic","year":"2010","unstructured":"Jankovic J, Jimenez-Shahed J, Brown LW. A randomised, double-blind, placebo-controlled study of topiramate in the treatment of Tourette syndrome. J Neurol Neurosurg Psychiatry. 2010;81:70\u20133.","journal-title":"J Neurol Neurosurg Psychiatry."},{"key":"580_CR94","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1097\/WNF.0b013e3181c295c1","volume":"33","author":"S-H Kuo","year":"2010","unstructured":"Kuo S-H, Jimenez-Shahed J. Topiramate in treatment of Tourette syndrome. Clin Neuropharmacol. 2010;33:32\u20134.","journal-title":"Clin Neuropharmacol."},{"key":"580_CR95","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/978-1-4684-2511-6_11","volume":"90","author":"HM Erickson","year":"1977","unstructured":"Erickson HM, Goggin JE, Messiha FS. Comparison of lithium and haloperidol therapy in Gilles de la Tourette syndrome. Adv Exp Med Biol. 1977;90:197\u2013205.","journal-title":"Adv Exp Med Biol."},{"key":"580_CR96","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1002\/ana.410210313","volume":"21","author":"CG Goetz","year":"1987","unstructured":"Goetz CG, Tanner CM, Wilson RS, Susan VC, Como PG, Shannon KM. Clonidine and Gilles de la Tourette\u2019s syndrome: double-blind study using objective rating methods. Ann Neurol. 1987;21:307\u201310.","journal-title":"Ann Neurol."},{"key":"580_CR97","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1080\/00048670802277222","volume":"42","author":"Y Du","year":"2008","unstructured":"Du Y, Li H, Vance A, Zhong Y, Jiao F, Wang H, et al. Randomized double-blind multicentre placebo-controlled clinical trial of the clonidine adhesive patch for the treatment of tic disorders. Aust N Z J Psychiatry. 2008;42:807\u201313.","journal-title":"Aust N Z J Psychiatry."},{"key":"580_CR98","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1176\/appi.ajp.158.7.1067","volume":"158","author":"L Scahill","year":"2001","unstructured":"Scahill L, Chappell PB, Kim YS, Schultz RT, Katsovich L, Shepherd E, et al. A placebo-controlled study of guanfacine in the treatment of children with tic disorders and attention deficit hyperactivity disorder. Am J Psychiatry. 2001;158:1067\u201374.","journal-title":"Am J Psychiatry."},{"key":"580_CR99","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1001\/archneur.60.7.996","volume":"60","author":"P O\u2019Suilleabhain","year":"2003","unstructured":"O\u2019Suilleabhain P, Dewey RB Jr. A randomized trial of amantadine in Huntington disease. Arch Neurol. 2003;60:996.","journal-title":"Arch Neurol."},{"key":"580_CR100","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1212\/WNL.59.5.694","volume":"59","author":"L Verhagen Metman","year":"2002","unstructured":"Verhagen Metman L, Morris MJ, Farmer C, Gillespie M, Mosby K, Wuu J, et al. Huntington\u2019s disease: a randomized, controlled trial using the NMDA-antagonist amantadine. Neurology. 2002;59:694\u20139.","journal-title":"Neurology."},{"key":"580_CR101","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1097\/WNF.0b013e3181ffde32","volume":"33","author":"S Pappa","year":"2010","unstructured":"Pappa S, Tsouli S, Apostolou G, Mavreas V, Konitsiotis S. Effects of amantadine on tardive dyskinesia: a randomized, double-blind, placebo-controlled study. Clin Neuropharmacol. 2010;33:271\u20135.","journal-title":"Clin Neuropharmacol."},{"key":"580_CR102","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1097\/00004714-199704000-00004","volume":"17","author":"S Angus","year":"1997","unstructured":"Angus S, Sugars J, Boltezar R, Koskewich S, Schneider NM. A controlled trial of amantadine hydrochloride and neuroleptics in the treatment of tardive dyskinesia. J Clin Psychopharmacol. 1997;17:88\u201391.","journal-title":"J Clin Psychopharmacol."},{"key":"580_CR103","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1055\/s-0042-102884","volume":"49","author":"W Zheng","year":"2016","unstructured":"Zheng W, Xiang Y-Q, Ng C, Ungvari G, Chiu H, Xiang Y-T. Extract of Ginkgo biloba for tardive dyskinesia: meta-analysis of randomized controlled trials. Pharmacopsychiatry. 2016;49:107\u201311.","journal-title":"Pharmacopsychiatry."},{"key":"580_CR104","doi-asserted-by":"crossref","first-page":"546","DOI":"10.4088\/JCP.v69n0405","volume":"69","author":"SW Woods","year":"2008","unstructured":"Woods SW, Saksa JR, Baker CB, Cohen SJ, Tek C. Effects of levetiracetam on tardive dyskinesia: a randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2008;69:546\u201354.","journal-title":"J Clin Psychiatry."},{"key":"580_CR105","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1002\/mds.22809","volume":"24","author":"A Curtis","year":"2009","unstructured":"Curtis A, Mitchell I, Patel S, Ives N, Rickards H. A pilot study using nabilone for symptomatic treatment in Huntington\u2019s disease. Mov Disord. 2009;24:2254\u20139.","journal-title":"Mov Disord."},{"key":"580_CR106","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1002\/1531-8257(200011)15:6<1252::AID-MDS1030>3.0.CO;2-I","volume":"15","author":"PJ van Wattum","year":"2000","unstructured":"van Wattum PJ, Chappell PB, Zelterman D, Scahill LD, Leckman JF. Patterns of response to acute naloxone infusion in Tourette\u2019s syndrome. Mov Disord. 2000;15:1252\u20134.","journal-title":"Mov Disord."},{"key":"580_CR107","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1212\/01.WNL.0000096019.71649.2B","volume":"61","author":"Huntington Study Group","year":"2003","unstructured":"Huntington Study Group. Dosage effects of riluzole in Huntington\u2019s disease: a multicenter placebo-controlled study. Neurology. 2003;61:1551\u20136.","journal-title":"Neurology."},{"key":"580_CR108","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.jns.2018.02.013","volume":"389","author":"A Macerollo","year":"2018","unstructured":"Macerollo A, Deuschl G. Deep brain stimulation for tardive syndromes: systematic review and meta-analysis. J Neurol Sci. 2018;389:55\u201360.","journal-title":"J Neurol Sci."},{"key":"580_CR109","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1001\/jamaneurol.2017.4317","volume":"75","author":"D Martinez-Ramirez","year":"2018","unstructured":"Martinez-Ramirez D, Jimenez-Shahed J, Leckman JF, Porta M, Servello D, Meng F-G, et al. Efficacy and safety of deep brain stimulation in Tourette syndrome. JAMA Neurol. 2018;75:353.","journal-title":"JAMA Neurol."},{"key":"580_CR110","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.pnpbp.2007.10.004","volume":"32","author":"CW Slotema","year":"2008","unstructured":"Slotema CW, van Harten PN, Bruggeman R, Hoek HW. Botulinum toxin in the treatment of orofacial tardive dyskinesia: a single blind study. Prog Neuropsychopharmacol Biol Psychiatry. 2008;32:507\u20139.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry."},{"key":"580_CR111","doi-asserted-by":"crossref","first-page":"054","DOI":"10.1055\/s-0035-1571217","volume":"36","author":"M Lotia","year":"2016","unstructured":"Lotia M, Jankovic J. Botulinum toxin for the treatment of tremor and tics. Semin Neurol. 2016;36:054\u201363.","journal-title":"Semin Neurol."}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40263-018-0580-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-018-0580-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-018-0580-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T19:15:41Z","timestamp":1775243741000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40263-018-0580-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,10]]},"references-count":111,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["580"],"URL":"https:\/\/doi.org\/10.1007\/s40263-018-0580-y","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,10]]},"assertion":[{"value":"10 October 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"No funding was received for the preparation of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Arjun Tarakad has no conflicts of interest relevant to the contents of this article. Joohi Jimenez-Shahed has received research funding and consulting fees from Auspex\/Teva, and consulting fees from Nuvelution and Bracket.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}